Memantine inhibits degradation of the articular cartilage extracellular matrix induced by advanced glycation end products (AGEs).
The accumulation of inflammation and cartilage damage induced by advanced glycation end products (AGEs) are important hallmarks of osteoarthritis (OA). Memantine is a clinically licensed drug used for the treatment of moderate and severe Alzheimer's disease. To date, little information has been reported regarding the effects of memantine on cartilage destruction. In this study, we investigated the protective effects of memantine on AGE-induced degradation of collagen II and aggrecans in human SW1353 chondrocytes. Our results indicate that memantine ameliorated AGE-induced degradation of collagen II and aggrecan at the post-translational level in SW1353 cells, which were mediated by matrix metalloproteinase-13 (MMP-13) and A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4), respectively. Mechanistically, memantine was found to attenuate the upregulation of the transcriptional factor interferon response factor-1 (IRF-1) induced by AGEs, as well as activation of the JAK2/STAT1 pathway. Our findings suggest that memantine may have a potential therapeutic effect in OA.